Daniel Pinto Joins Johnson & Johnson's Board in Major Healthcare-Finance Leadership Move

A Financial Executive with Decades of Global Markets Experience Takes Strategic Role

Daniel Pinto, the departing President of JPMorgan Chase, has been appointed to Johnson & Johnson’s Board of Directors, marking a significant convergence between financial services and healthcare innovation leadership. The appointment underscores the growing importance of deep financial acumen in guiding major pharmaceutical and medical technology enterprises through complex market dynamics.

Pinto brings to the role an extraordinary career spanning over 30 years within JPMorgan Chase and its antecedent institutions. His professional journey began in 1983 as a financial analyst and foreign exchange trader at Manufacturers Hanover in Buenos Aires, where he initially built expertise in emerging markets and capital flows. His career trajectory has been marked by progressive advancement across the organization’s most critical functions.

Ascending Through Global Markets Leadership

Throughout the 1990s and 2000s, Pinto expanded his influence across JPMorgan Chase’s international operations. He led sales operations at Chemical Bank in Mexico during the early 1990s, subsequently moved to London in 1996 to oversee trading and market operations spanning Eastern Europe, the Middle East, Africa, and Asia. By 2006, he had risen to become global head of Emerging Markets, eventually overseeing Credit Trading, Syndication, and Fixed Income operations within the Investment Banking division.

His elevation to co-CEO of the Corporate & Investment Bank in 2012, followed by his appointment as sole CEO in 2014, positioned him as one of the financial industry’s most influential figures. In January 2018, Pinto was named Co-President and Chief Operating Officer, collaborating directly with the firm’s leadership to identify major strategic opportunities. He transitioned to sole President and COO in January 2022—a role he maintains until June 30, 2025, after which he will serve as Vice Chairman through the end of 2026.

Perspective and Global Insight

Johnson & Johnson’s leadership expressed enthusiasm about the appointment. Joaquin Duato, Chairman and Chief Executive Officer, noted that Pinto’s exceptional financial expertise and comprehensive understanding of global capital markets would provide invaluable perspective for the company’s ongoing investments in healthcare innovation. Pinto, for his part, emphasized his long-standing respect for Johnson & Johnson’s commitment to scientific advancement and its mission to address complex and challenging diseases affecting patients worldwide.

Pinto earned his bachelor’s degree in Public Accounting and Business Administration from Universidad Nacional de Lomas de Zamora in Buenos Aires. He currently serves as a board member of the Institute of International Finance, further solidifying his influence within global financial governance structures.

Why This Appointment Matters

The addition of a senior financial executive with Pinto’s credentials reflects a broader industry trend: healthcare companies increasingly recognize the strategic value of capital markets expertise when navigating innovation investment, capital allocation, and global expansion. Pinto’s decades of experience managing complex financial institutions positions him to guide Johnson & Johnson through evolving regulatory environments, investor relations dynamics, and the substantial capital requirements inherent in developing next-generation medical solutions.

Johnson & Johnson continues to leverage its competitive advantages in pharmaceutical innovation and medical device manufacturing to address an expansive spectrum of healthcare challenges—from preventive care to treatment of complex diseases—reinforcing its position as a leader in advancing patient outcomes globally.